|Tested species reactivity||Human, Mouse, Rat|
|Published species reactivity||Rat, Human, Mouse, Not Applicable|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Recombinant full length protein (Human).|
|Storage buffer||PBS with 0.2% gelatin|
|Contains||0.1% sodium azide|
|Storage Conditions||4° C, do not freeze|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||Assay dependent|
|Immunoprecipitation (IP)||Assay dependent|
|Western Blot (WB)||1:100|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (Paraffin) (IHC (P))||See 2 publications below|
|Immunohistochemistry (IHC)||See 12 publications below|
|Western Blot (WB)||See 10 publications below|
|Miscellaneous PubMed (MISC)||See 1 publications below|
|Gel Shift (GS)||See 1 publications below|
|Immunocytochemistry (ICC)||See 1 publications below|
MA1-34070 detects RB1 from mouse, rat, and human samples.
MA1-34070 has been successfully used in immunoprecipitation, immunohistochemistry (paraffin tissue), and Western blot applications. A suggested positive control is K562 WCL.
The MA1-34070 immunogen is recombinant full length protein (Human).
The protein encoded by this gene is a negative regulator of the cell cycle and was the first tumor suppressor gene found. The encoded protein also stabilizes constitutive heterochromatin to maintain the overall chromatin structure. The active, hypophosphorylated form of the protein binds transcription factor E2F1. Defects in this gene are a cause of childhood cancer retinoblastoma (RB), bladder cancer, and osteogenic sarcoma.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
MA1-34070 was used in immunohistochemistry - paraffin section to run phase II single-arm trial of CDK4/6 inhibitor palbociclib in Rb-positive advanced breast cancer
|DeMichele A,Clark AS,Tan KS,Heitjan DF,Gramlich K,Gallagher M,Lal P,Feldman M,Zhang P,Colameco C,Lewis D,Langer M,Goodman N,Domchek S,Gogineni K,Rosen M,Fox K,O'Dwyer P||Clinical cancer research : an official journal of the American Association for Cancer Research (21:995)||2015|
Immunohistochemical analysis of expressions of RB1, CDK4, HSP90, cPLA2G4A, and CHMP2B is helpful in distinction between myxofibrosarcoma and myxoid liposarcoma.
MA1-34070 was used in immunohistochemistry - paraffin section to determine the role and diagnostic efficacy of RB1, CDK4, CHMP2B, HSP90, and cPLA2G4A as markers in myxofibrosarcomas and myxoid liposarcomas
|Wang T,Goodman MA,McGough RL,Weiss KR,Rao UN||International journal of surgical pathology (22:589)||2014|
RB1 gene in Merkel cell carcinoma: hypermethylation in all tumors and concurrent heterozygous deletions in the polyomavirus-negative subgroup.
MA1-34070 was used in immunohistochemistry to study retinoblastoma protein-1 gene methylation and heterozygous loss in polyomavirus-negative Merkel cell carcinoma
|Sahi H,Savola S,Sihto H,Koljonen V,Bohling T,Knuutila S||APMIS : acta pathologica, microbiologica, et immunologica Scandinavica (122:1157)||2014|
Human papilloma virus genome is rare in North American non-small cell lung carcinoma patients.
MA1-34070 was used in immunohistochemistry to study the lack of association of HPV with non-small cell lung cancer in Canadian and North American populations
|Yanagawa N,Wang A,Kohler D,Santos Gda C,Sykes J,Xu J,Pintilie M,Tsao MS||Lung cancer (Amsterdam, Netherlands) (79:215)||2013|
Alteration of G1/S transition regulators influences recurrences in head and neck squamous carcinomas.
MA1-34070 was used in immunohistochemistry to study the role of the G1/S transition regulators in the recurrence of head and neck squamous carcinomas
|Canzonieri V,Barzan L,Franchin G,Vaccher E,Talamini R,Sulfaro S,Baldassarre G||Journal of cellular physiology (227:233)||2012|
Simultaneous aberrations of single CDKN2A network components and a high Rb phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas.
MA1-34070 was used in immunohistochemistry to identify biomarkers to classify primary cutaneous B-cell lymphomas
|Kaune KM,Neumann C,Hallermann C,Haller F,Schön MP,Middel P||Experimental dermatology (20:331)||2011|
Prognostic significance of the alterations of the G1-S checkpoint in localized leiomyosarcoma of the peripheral soft tissue.
MA1-34070 was used in immunohistochemistry to study the prognositic value of alterations in the G1-S checkpoint in localized leiomyosarcoma of the peripheral soft tissue
|Panelos J,Beltrami G,Scoccianti G,Capanna R,Paglierani M,Pepi M,Massi D,Franchi A||Annals of surgical oncology (18:566)||2011|
Defining a molecular phenotype for benign and malignant parathyroid tumors.
MA1-34070 was used in immunohistochemistry to define a molecular profile for benign and malignant parathyroid tumor discrimination
|Fernandez-Ranvier GG,Khanafshar E,Tacha D,Wong M,Kebebew E,Duh QY,Clark OH||Cancer (115:334)||2009|
Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer.
MA1-34070 was used in immunohistochemistry to investigate the expression of double-strand break repair genes in non-small cell lung cancer
|Lee MN,Tseng RC,Hsu HS,Chen JY,Tzao C,Ho WL,Wang YC||Clinical cancer research : an official journal of the American Association for Cancer Research (13:832)||2007|
The expressions of the Rb pathway in cervical intraepithelial neoplasia; predictive and prognostic significance.
MA1-34070 was used in immunohistochemistry to study the clinical value of measuring retinoblastoma pathway expression in cervical intraepithelial neoplasia
|Nam EJ,Kim JW,Kim SW,Kim YT,Kim JH,Yoon BS,Cho NH,Kim S||Gynecologic oncology (104:207)||2007|
Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder.
MA1-34070 was used in immunohistochemistry to study the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder
|Yurakh AO,Ramos D,Calabuig-Fariñas S,López-Guerrero JA,Rubio J,Solsona E,Romanenko AM,Vozianov AF,Pellin A,Llombart-Bosch A||European urology (50:506)||2006|
p53, p16 and cyclin D1: molecular determinants of radiotherapy treatment response in oral carcinoma.
MA1-34070 was used in immunohistochemistry to study the molecular determinants of the response to radiotherapy in oral carcinoma
|Jayasurya R,Francis G,Kannan S,Lekshminarayanan K,Nalinakumari KR,Abraham T,Abraham EK,Nair MK||International journal of cancer (109:710)||2004|
The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
MA1-34070 was used in immunohistochemistry to study p53, p16 and Rb protein expression and the clinicopathology of patients with locally advanced urinary bladder cancer
|Tzai TS,Tsai YS,Chow NH||Urologic oncology (22:112)||2004|
p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2.
MA1-34070 was used in immunohistochemistry to study the effects of epigenetic silencing of p14ARF on the subcellular localization of MDM2
|Esteller M,Cordon-Cardo C,Corn PG,Meltzer SJ,Pohar KS,Watkins DN,Capella G,Peinado MA,Matias-Guiu X,Prat J,Baylin SB,Herman JG||Cancer research (61:2816)||2001|
HFE polymorphisms influence the response to chemotherapeutic agents via induction of p16INK4A.
MA1-34070 was used in western blot to study the role of p16INK4A in the mechanism by which HFE polymorphisms affect the response of cancer cells to chemotherapy
|Lee SY,Liu S,Mitchell RM,Slagle-Webb B,Hong YS,Sheehan JM,Connor JR||International journal of cancer (129:2104)||2011|
Selective inhibition of rRNA transcription downregulates E2F-1: a new p53-independent mechanism linking cell growth to cell proliferation.
MA1-34070 was used in western blot to investigate the influence of selective inhibition of rRNA transcription on the cell cycle of human cancer cells
|Donati G,Brighenti E,Vici M,Mazzini G,Treré D,Montanaro L,Derenzini M||Journal of cell science (124:3017)||2011|
Activation of Wnt signaling pathway by human papillomavirus E6 and E7 oncogenes in HPV16-positive oropharyngeal squamous carcinoma cells.
MA1-34070 was used in western blot to investigate the effect of E6/E7 viral oncoproteins on Wnt signaling pathway in HPV16-positive oropharyngeal cancer cells
|Rampias T,Boutati E,Pectasides E,Sasaki C,Kountourakis P,Weinberger P,Psyrri A||Molecular cancer research : MCR (8:433)||2010|
Establishment of ponasterone A-inducible the wild-type p53 protein-expressing clones from HSC-1 cells, cell growth suppression by p53 expression and the suppression mechanism.
MA1-34070 was used in western blot to evaluate an inducible p53 expressing cell clone for p53 gene therapy in cancers
|Hori M,Suzuki K,Udono MU,Yamauchi M,Mine M,Watanabe M,Kondo S,Hozumi Y||Archives of dermatological research (301:631)||2009|
E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells.
MA1-34070 was used in western blot to study the E6 and E7 gene silencing and its effect on human papillomavirus 16-positive oropharyngeal cancer cells
|Rampias T,Sasaki C,Weinberger P,Psyrri A||Journal of the National Cancer Institute (101:412)||2009|
The inhibition of T-cells proliferation by mouse mesenchymal stem cells through the induction of p16INK4A-cyclin D1/cdk4 and p21waf1, p27kip1-cyclin E/cdk2 pathways.
MA1-34070 was used in western blot to study the molecular mechanisms by which mesenchymal stem cells inhibit T cell proliferation
|Kim JA,Hong S,Lee B,Hong JW,Kwak JY,Cho S,Kim CC||Cellular immunology (245:16)||2007|
Ixocarpalactone A isolated from the Mexican tomatillo shows potent antiproliferative and apoptotic activity in colon cancer cells.
MA1-34070 was used in western blot to study the antiproliferative and apoptotic effects of ixocarpalactone A on colon cancer cells
|Choi JK,Murillo G,Su BN,Pezzuto JM,Kinghorn AD,Mehta RG||The FEBS journal (273:5714)||2006|
Inhibitory effect of caffeic acid phenethyl ester on the growth of C6 glioma cells in vitro and in vivo.
MA1-34070 was used in western blot to study the inhibition of C6 glioma cell growth by caffeic acid phenethyl ester and the potential mechanisms involved
|Kuo HC,Kuo WH,Lee YJ,Lin WL,Chou FP,Tseng TH||Cancer letters (234:199)||2006|
Evidence that high telomerase activity may induce a senescent-like growth arrest in human fibroblasts.
MA1-34070 was used in western blot to study the involvement of telomerase activity in human fibroblast growth arrest
|Gorbunova V,Seluanov A,Pereira-Smith OM||The Journal of biological chemistry (278:7692)||2003|
Dominant negative c-jun inhibits activation of the cyclin D1 and cyclin E kinase complexes.
MA1-34070 was used in western blot to investigate the effect of the dominant negative c-jun on the activation of cyclin D1 and cyclin E kinase complexes
|Hennigan RF,Stambrook PJ||Molecular biology of the cell (12:2352)||2001|
SKI promotes Smad3 linker phosphorylations associated with the tumor-promoting trait of TGFbeta.
MA1-34070 was used in western blot to discuss how SKI-mediated processes in melanoma cells
|Lin Q,Chen D,Timchenko NA,Medrano EE||Cell cycle (Georgetown, Tex.) (9:1684)||2010|
|Not Applicable||Not Cited||
E2F4 and ribonucleotide reductase mediate S-phase arrest in colon cancer cells treated with chlorophyllin.
MA1-34070 was used in EMSA and western blot to investigate the cellular effects of chlorophyllin treatment
|Chimploy K,Díaz GD,Li Q,Carter O,Dashwood WM,Mathews CK,Williams DE,Bailey GS,Dashwood RH||International journal of cancer (125:2086)||2009|
Different effects of ribosome biogenesis inhibition on cell proliferation in retinoblastoma protein- and p53-deficient and proficient human osteosarcoma cell lines.
MA1-34070 was used in immunocytochemistry and western blot to study the effects of rRNA synthesis inhibition on cell cycle progression and cell population growth according to retinoblastoma and p53 status
|Montanaro L,Mazzini G,Barbieri S,Vici M,Nardi-Pantoli A,Govoni M,Donati G,Treré D,Derenzini M||Cell proliferation (40:532)||2007|